Welcome to our dedicated page for Polyrizon news (Ticker: PLRZ), a resource for investors and traders seeking the latest updates and insights on Polyrizon stock.
Polyrizon Ltd (PLRZ) is a clinical-stage biotechnology company pioneering intranasal hydrogel solutions for respiratory protection and targeted drug delivery. This page provides official updates on the company's progress, partnerships, and innovations in preventive healthcare technologies.
Access timely announcements about clinical trial developments, manufacturing agreements, and patent filings related to Polyrizon's Capture & Contain (C&C™) and Trap & Target (T&T™) platforms. Investors and researchers will find verified information about the company's GMP-compliant production processes and collaborative research initiatives.
Key updates include progress on PL-14 allergy blocker trials, intellectual property expansions, and strategic partnerships supporting therapeutic applications of Polyrizon's hydrogel technology. All content is curated to meet investor needs for decision-ready information while maintaining regulatory compliance standards.
Bookmark this page for direct access to Polyrizon's latest advancements in nasal barrier technology and drug delivery systems. Check regularly for authoritative updates from primary sources.
Polyrizon (NASDAQ: PLRZ) has announced successful preliminary safety study results for its PL-14 Allergy Blocker formulation, tested on human nasal tissue using the MucilAir™ model. The study evaluated the local tolerability of the mucoadhesive nasal gel spray, designed to create a physical barrier against airborne allergens with a 4-hour effectiveness window.
The safety assessment measured key indicators including tissue integrity, cytotoxicity, cilia beating frequency, mucociliary clearance, and inflammatory response. Results showed tissue viability and function remained consistent with baseline and vehicle controls, with no signs of inflammatory activation or functional impairment.
This milestone supports Polyrizon's regulatory strategy and upcoming FDA pre-submission meeting. The company plans to initiate U.S. and European clinical trials in late 2025 or early 2026.
Polyrizon (Nasdaq: PLRZ) has received a notification from Nasdaq on April 8, 2025, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until October 6, 2025 to meet the requirement.
To regain compliance, PLRZ's closing bid price must exceed $1.00 for at least 10 consecutive business days. If unsuccessful, the company may qualify for an additional 180-day period, provided it meets other Nasdaq Capital Market listing criteria. Failure to comply could result in delisting from Nasdaq.
Polyrizon (Nasdaq: PLRZ) has partnered with a leading global branding and trademark consultancy firm to develop strategic branding for its Capture and Contain™ (C&C) hydrogel technology. The collaboration aims to create brand identity for their innovative intranasal spray formulation, which creates a protective biological barrier against allergens and viruses.
The engagement includes comprehensive trademark screening and linguistic evaluations across U.S. and European markets to ensure brand viability and regulatory compliance. The brand development process is scheduled to align with Polyrizon's ongoing clinical and regulatory milestones.
Polyrizon (NASDAQ: PLRZ) has successfully closed a $17.0 million private placement of Ordinary Shares and warrants. The offering included 35,416,667 Ordinary Units priced at $0.48 per unit, with each unit comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant.
The Series A Warrants, exercisable for 30 months after shareholder approval, have an initial exercise price of $1.20 per Ordinary Share. Pre-Funded Warrants are priced at $0.47999 with a $0.00001 exercise price. The company plans to use the proceeds for general corporate purposes and working capital.
Aegis Capital Corp. served as the exclusive placement agent. The securities were offered privately to accredited investors and are not registered under the Securities Act. Polyrizon has agreed to file registration statements with the SEC for the resale of the shares and warrant-exercisable shares.
Polyrizon (NASDAQ: PLRZ) has secured a $17.0 million private placement through definitive agreements with institutional investors. The offering includes 35,416,667 Ordinary Units priced at $0.48 per unit, consisting of either Ordinary Shares or Pre-Funded Warrants, plus Series A Warrants.
Each Series A Warrant, exercisable after shareholder approval, has an initial exercise price of $1.20 per Ordinary Share with a 30-month term. Pre-Funded Warrants are priced at $0.47999 with a $0.00001 exercise price. The transaction is expected to close around April 1, 2025.
The company plans to use the proceeds for general corporate purposes and working capital. Aegis Capital Corp. serves as the exclusive placement agent. The securities are being sold in a private placement to accredited investors and will require registration for resale.
Polyrizon (Nasdaq: PLRZ) has announced its clinical strategy for PL-14, an intranasal allergy blocker designed for seasonal allergic rhinitis. The company has structured a comprehensive clinical plan ahead of a pre-submission meeting with the FDA.
The clinical studies will evaluate three key aspects:
- Efficacy and safety under natural exposure during peak allergy season
- Human Factors study for usability and patient acceptance
- Assessment of nasal residence time of the PL-14 formulation
The biotech company plans to initiate clinical trials in the U.S. and Europe between late 2025 and early 2026, following preclinical work completion and FDA consultation.
Polyrizon (NASDAQ: PLRZ) has initiated preclinical studies for intranasal Benzodiazepines (BZDs) using its proprietary Trap and Target™ (T&T) platform for treating acute repetitive seizures and status epilepticus. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, will evaluate drug loading capacity, release kinetics, nasal deposition, and stability.
The global acute repetitive seizures market, valued at $3.15 billion in 2024, is projected to grow at a 12.7% CAGR from 2025-2030. Additionally, the epilepsy treatment devices market is expected to reach $787.3 Million by 2033, growing at a 4.1% CAGR.
The initiative aims to develop a faster, safer, and more accessible solution for managing acute seizures outside clinical settings, targeting the approximately 50 million people worldwide affected by epilepsy according to WHO data.
Polyrizon (Nasdaq: PLRZ) has signed a non-binding Letter of Intent (LOI) with an unnamed biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatments. The collaboration will leverage Polyrizon's proprietary intranasal hydrogel platform to optimize drug delivery.
Under the LOI terms, Polyrizon will lead the formulation development using its mucoadhesive drug delivery technology, while the psychedelic company will fund research and development, including feasibility studies. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP ownership, commercialization rights, and financial terms, with Polyrizon receiving royalties on future product commercialization.
Polyrizon (Nasdaq: PLRZ) has initiated preclinical studies for intranasal Naloxone using their proprietary Trap and Target™ (T&T) platform. The studies, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, will evaluate key parameters including drug loading capacity, release kinetics, nasal deposition, and stability.
The company aims to enhance intranasal Naloxone delivery to combat the global opioid crisis by potentially offering higher bioavailability and optimized drug release profiles. This development targets the growing Naloxone market, projected to reach $2.47 billion by 2032 with an 11% CAGR, where the intranasal spray segment alone is expected to reach $1.4 billion by 2030.
Intranasal delivery offers several advantages including easier administration, no need for trained medical personnel, reduced needlestick injury risks, and increased accessibility for emergency responders and at-risk individuals.
Polyrizon (Nasdaq: PLRZ), a development stage biotech company focused on innovative intranasal hydrogels, has announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC).
The report is accessible through the SEC's website and Polyrizon's Investor Relations website. Shareholders can request free copies of the annual report by contacting the company's Investor Relations Department.